Arena Pharmaceuticals Inc (ARNA.OQ)
ARNA.OQ on NASDAQ Stock Exchange Global Select Market
6.85USD
1 Aug 2013
6.85USD
1 Aug 2013
Price Change (% chg)
$-0.10 (-1.44%)
$-0.10 (-1.44%)
Prev Close
$6.95
$6.95
Open
$7.15
$7.15
Day's High
$7.15
$7.15
Day's Low
$6.84
$6.84
Volume
422,842
422,842
Avg. Vol
1,060,947
1,060,947
52-wk High
$10.99
$10.99
52-wk Low
$6.65
$6.65
About
Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s... (more)
Overall
| Beta: | 0.17 |
| Market Cap (Mil.): | $1,513.55 |
| Shares Outstanding (Mil.): | 217.78 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ARNA.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.37 | -- | -- |
| ROI: | -40.40 | -2.58 | 18.76 |
| ROE: | -124.20 | -2.66 | 19.59 |
Arena withdraws diet drug application in Europe; shares fall
- Arena Pharmaceuticals Inc withdrew an application to market its anti-obesity drug in the European Union, sending its shares down 15 percent in after-hours trading.
Competitors
| Price | Change | |
|---|---|---|
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| GlaxoSmithKline plc (GSK.L) | 1,705.80p | +20.00 |
| Orexigen Therapeutics, Inc. (OREX.OQ) | $7.69 | +0.09 |
| VIVUS, Inc. (VVUS.OQ) | $15.00 | +0.19 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

